A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder

P.2.c.018 Efficacy and tolerability of multiple doses of LU AA21004 in an 8-week trial of adults with major depressive disorder

(2011) N. Henigsberg et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD)

(2011) David S. Baldwin et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder

(2011) Enric Alvarez et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder

(2011) Benny Bang-Andersen et al.   JOURNAL OF MEDICINAL CHEMISTRY

Do Efficacy and Effectiveness Samples Differ in Antidepressant Treatment Outcome?

(2010) Florian Seemüller et al.   JOURNAL OF CLINICAL PSYCHIATRY

Prediction of Recurrence in Recurrent Depression

(2010) Mascha C. ten Doesschate et al.   JOURNAL OF CLINICAL PSYCHIATRY